A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

The randomised, double-blind and placebo-controlled trial involved 35 healthy participants, who were each given a single ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

Amgen, AstraZeneca focus on asthmatic punk rocker to show how Tezspire can unleash lust for life In the WAYPOINT study, ...

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving ...

Related: Ozempic (Semaglutide) - Subcutaneous When a drug is on the FDA shortage list, compounding pharmacies can legally mix ...

Johnson & Johnson announced the submission of regulatory applications to the U.S. FDA and European Medicines Agency seeking approval of a ...

FinGo is expected to complement SMX’s tracing and authentication from source through its Human Identity-as-a-Service (HIDaaS) ...

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks ...